IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
Titel:
IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
Auteur:
Califano, R. Każarnowicz, A. Karaseva, N. Sánchez, A. Liu, S.V. Horn, L. Quach, C. Yu, W. Kabbinavar, F. Lam, S. Mansfield, A.